An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL.

Blood Adv · 2024 · PMC11176945 · PMID 38598745

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

only marginally significantno p-value reported

In addition, some of the results in either direction were only marginally significant or nonsignificant.

also in 5,076 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.